Compare ROIV & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | EVR |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 11.7B |
| IPO Year | N/A | 2006 |
| Metric | ROIV | EVR |
|---|---|---|
| Price | $21.33 | $367.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $24.31 | ★ $332.22 |
| AVG Volume (30 Days) | ★ 8.3M | 302.4K |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ 12.55 |
| Revenue | $20,329,000.00 | ★ $3,542,875,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | $741.42 | $16.43 |
| P/E Ratio | ★ N/A | $27.99 |
| Revenue Growth | N/A | ★ 27.03 |
| 52 Week Low | $8.73 | $148.63 |
| 52 Week High | $23.47 | $364.42 |
| Indicator | ROIV | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 69.62 |
| Support Level | $21.36 | $338.95 |
| Resistance Level | $22.21 | $353.30 |
| Average True Range (ATR) | 0.73 | 8.97 |
| MACD | -0.17 | 0.68 |
| Stochastic Oscillator | 19.30 | 82.40 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.